Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 0.61 |
| ▸ | CA2 | P00918 | 10/20 | 0.61 |
| ▸ | CA9 | Q16790 | 8/20 | 0.61 |
| ▸ | CA12 | O43570 | 3/20 | 0.61 |
| ▸ | CA7 | P43166 | 3/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.61 |
| ▸ | CA3 | P07451 | 2/20 | 0.61 |
| ▸ | CA4 | P22748 | 2/20 | 0.61 |
| ▸ | CA6 | P23280 | 2/20 | 0.61 |
| ▸ | CA5A | P35218 | 2/20 | 0.61 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.61 |
| ▸ | RECQL | P46063 | 2/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | FNTA | P49354 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL185577 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 | |
| SCHEMBL186596 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 | |
| SCHEMBL148281 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 | |
| SCHEMBL147680 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 | |
| SCHEMBL1655279 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 | |
| SCHEMBL11064484 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 | |
| SCHEMBL374532 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 | |
| SCHEMBL10715880 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 | |
| SCHEMBL143597 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 | |
| SCHEMBL22283885 | 1.00 | CA1 (0.61) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117822065-A | Preparation method and application of template-free emulsion plating solution for preparing porous metal | 哈尔滨工业大学(深圳)(哈尔滨工业大学深圳科技创新研究院) | 2024-04-05 | — | — | CN | claimed |
| US-20250197784-A1 | PIGMENT UNIT DOSE DETERGENT | HENKEL AG & CO. KGAA (DE) | 2025-06-19 | — | — | US | disclosed |
| US-20250197773-A1 | SELF PRESERVED MILD LIQUID DETERGENT | HENKEL AG & CO. KGAA (DE) | 2025-06-19 | — | — | US | disclosed |
| CN-117822065-A | Preparation method and application of template-free emulsion plating solution for preparing porous metal | 哈尔滨工业大学(深圳)(哈尔滨工业大学深圳科技创新研究院) | 2024-04-05 | — | — | CN | disclosed |
| US-20230181571-A1 | USE OF METHYLNALTREXONE TO ATTENUATE TUMOR PROGRESSION | SALIX PHARMACEUTICALS, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230149389-A1 | METHODS OF REDUCING MORTALITY IN SUBJECTS SUFFERING FROM AN UNDERLYING DISEASE OR CONDITION BY ADMINISTRATION OF METHYLNALTREXONE | BAUSCH HEALTH IRELAND LIMITED (IE) | 2023-05-18 | — | — | US | disclosed |
| US-20220175764-A1 | USE OF METHYLNALTREXONE AND RIFAXIMIN FOR TREATMENT OF INCREASED GUT PERMEABILITY OR ASSOCIATED DISORDERS | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-06-09 | — | — | US | disclosed |
| US-8524276-B2 | Oral formulations and lipophilic salts of methylnaltrexone | WYETH, LLC (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120070495-A1 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE | WYETH LLC (US) | 2012-03-22 | — | — | US | disclosed |
| EP-2371357-A1 | Oral formulations and lipophilic salts of methylnaltrexone | Wyeth LLC (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2011112816-A1 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE | WYETH, LLC (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070495-A1 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE | OPRL1, OPRM1, OPRK1 | CA1 3999/4885CA2 3378/4885CA9 3764/4885 |
| US-20230181571-A1 | USE OF METHYLNALTREXONE TO ATTENUATE TUMOR PROGRESSION | MTNR1A, OPRL1, OPRK1 | CA1 2143/4885CA2 2836/4885CA9 2604/4885 |
| US-20230149389-A1 | METHODS OF REDUCING MORTALITY IN SUBJECTS SUFFERING FROM AN UNDERLYING DISEASE OR CONDITION BY ADMINISTRATION OF METHYLNALTREXONE | SLC10A2, OPRL1, OGFR | CA1 1744/4885CA2 911/4885CA9 3200/4885 |
| US-20220175764-A1 | USE OF METHYLNALTREXONE AND RIFAXIMIN FOR TREATMENT OF INCREASED GUT PERMEABILITY OR ASSOCIATED DISORDERS | SLC10A2, SLC10A1, NR1H4 | CA1 4733/4885CA2 3899/4885CA9 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.